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Do inhaled steroids increase 
the risk of osteoporosis?
e v i d e n c e - b a s e d  a n s w e r
The	use	of	inhaled	corticosteroids	at	conven-
tional	doses	for	asthma	and	chronic	obstruc-
tive	pulmonary	disease	(CoPD)	does	not	ap-
pear	to	be	associated	with	significant	bone	
loss	 at	 2	 to	 3	 years	 of	 follow-up	 (strength	
of	 recommendation	 [sor]:	 A,	 systematic	
reviews	 and	 randomized	 controlled	 trials	
[rCTs]).	 However,	 higher	 doses	 of	 inhaled	
corticosteroids	may	be	associated	with	neg-
ative	bone	density	changes	at	up	to	4	years	
of	follow-up	(sor:	C,	rCTs	without	change	in	
fracture	rates).	No	evidence	exists	to	evaluate	
whether	nasal	steroids	increase	the	risks	of	
bone	loss.	longer-term	effects	of	prolonged	
use	of	 inhaled	steroids	on	bMD	or	 fracture	
risk	are	undetermined	with	current	evidence.
c l i n i c a l  c o m m e n t a r y
Encourage weight-bearing and aerobic 
exercise to all asthma or COPD patients
asthma	and	CoPD	are	 prevalent	 among	
the	 underserved	 patients	 I	 see.	 Inhaled	
steroids	are	difficult	 for	 these	patients	 to	
obtain.	once	 they	 feel	better,	many	stop	
using	the	steroid	until	symptoms	return.	
			although	we	do	not	usually	prescribe	at	
the	higher	doses	described	in	the	review,	
our	goal	has	always	been	long-term	treat-
ment.	If	these	medications	can	cause	os-
teoporosis	with	longer	use,	it	may	become	
an	 additional	 deterrent	 to	 adherence.	
However,	 consistent	 use	 may	 reduce	
the	 use	 of	 oral	 steroids	 for	 acute	 ex-
acerbations,	 potentially	 even	 reducing	
bone	loss.	
encourage	 weight-bearing	 and	 aerobic	
exercise	 for	 osteoporosis	 prevention	 and	
balance	 exercises	 to	 prevent	 falls	 for	 all	
asthma	or	CoPD	patients.	These	exercises	
may	 be	 prudent	 prevention	 for	 both	 lung	
disease	and	osteoporotic	fractures.
José E. Rodríguez, MD 
florida	state	university	College	of	Medicine,	
Tallahassee
n Evidence summary
Inhaled corticosteroids are the primary 
therapy for asthma and are common-
ly prescribed for chronic obstructive 
pulmonary disease. The use of oral 
steroids is a well-known risk factor 
for osteoporosis, but the effects of 
inhaled corticosteroids on bone min-
eral density (BMD) are not well 
defined.
No significant changes seen  
in BMD at moderate doses
Our search found evidence pertaining to 
the use of inhaled pulmonary steroids, 
but no evidence meeting our inclusion 
criteria about the effect of inhaled nasal 
steroids. We located a Cochrane review, 
1 other meta-analysis, and 2 individual 
RCTs that were not included in the sys-
tematic reviews. Three of the 7 RCTs 
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included in the 2002 Cochrane review 
met our inclusion criteria for evaluat-
ing the impact of inhaled corticosteroids 
on BMD or fracture rate for adults with 
asthma or COPD.
All 3 RCTs (792 subjects total) ex-
amined the effect of conventional doses 
of inhaled corticosteroids on BMD and 
2 of the RCTs (892 participants total) 
collected fracture data. No demonstra-
ble effect was seen on vertebral fracture 
(odds ratio [OR]=1.87; 95% confidence 
interval [CI], 0.5–7.03) or BMD at 2 
years follow-up.1 The subjects were oth-
erwise healthy people with asthma or 
COPD with an average age of 40 years; 
men outnumbered women 2 to 1.
A fair-quality 2004 meta-analysis 
of 14 randomized trials (2300 partici-
pants) included 2 studies (448 subjects) 
that overlapped with the Cochrane 
review. There were no significant chang-
es in BMD with moderately high doses 
of inhaled corticosteroids at 1 to 3 years 
follow-up.2 
Annual changes in lumbar and 
femoral neck BMD (–0.23% and 
–0.17%, respectively) were not sta-
tistically significant. Mean changes in 
lumbar BMD were not significantly 
different from controls (–0.02). A fair-
quality 2004 RCT did not demonstrate 
any clinically relevant effect on BMD at 
2 years follow-up. This study used 800 
mcg/day of fluticasone for patients with 
mild asthma.3 
BMD changes found  
at higher doses
There is, however, some evidence that 
higher doses of inhaled corticosteroids can 
result in adverse BMD changes. In a high-
quality RCT of 412 participants, aged 
40 to 69 years, with mild to moderate 
COPD, use of higher-dose triamcino-
lone (1200 mcg/day) was associated with 
decreased lumbar and femoral neck BMD 
over 3 to 4 years.4 The differences in 
BMD between the inhaled corticosteroids 
and placebo groups at the femoral neck 
and lumbar spine were 1.78% (P<.001) 
and 1.33% (P=.007), respectively. How-
ever, the risk of fracture or height loss did 
not increase at follow-up. 
A large fair-quality RCT from 2001 
included in both meta-analyses dem-
onstrated a dose-related fall in BMD 
within the subjects over 2 years at 
the lumbar spine (standard deviation, 
3.4%; P<.010). This finding remained 
statistically significant after adjusting 
for asthma severity, but BMD changes 
were not different between the inhaled 
corticosteroids and placebo groups. 
However, this finding may be the result 
of higher oral corticosteroids use in the 
reference group.5 
Limitations of these studies
These studies, though, have limitations. 
The follow-up periods for all of these 
studies are less than 5 years, and thus 
the longer-term effects of prolonged use 
of inhaled corticosteroids on BMD or 
fracture risk cannot be determined with 
this evidence. Furthermore, the study 
populations were relatively young, with 
few other risk factors (they were, for ex-
ample, predominantly male) than popu-
lations at highest risk for osteoporosis 
and fracture. These factors limit inter-
pretation of the data for long-term in-
haled corticosteroids use, particularly in 
populations with higher baseline osteo-
porosis risk—older persons with chron-
ic lung disease who take inhaled corti-
costeroids for more than 2 to 3 years. 
We need better and longer-term studies 
to help advise our patients about the 
risks and benefits of inhaled corticoste-
roids therapy. 
Recommendations from others
The New Zealand Guideline Group 
says the risk of reduced BMD increased 
with long-term, high-dose inhaled 
corticosteroids.6 The Institute for Clini-
cal Systems Improvement guidelines 
recommends considering osteoporosis 
inhaled steroids and osteoporosis risk p
Inhaled steroids  
at conventional 
doses do not 
seem to cause 
significant bone 
loss; higher doses 
might
prevention measures for those who have 
been (or will be) taking a daily high-
dose inhaled glucocorticoid for several 
years as glucocorticoid use compounds 
fracture risk beyond that determined 
solely by BMD.7 
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